OakChart

Relmada Therapeutics Inc

RLMDHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 2:27 PM ET

4.47+0.20 (4.57%)
2026-11-11 20:27 CET
Market cap
455.48 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-61.93 USD m
Free cash flow, TTM
-45.99 USD m
EPS diluted, TTM
-0.93
P/E
-
Compare

Price

RLMD against its 20, 50 and 200-day averages
2050200beatmissearnings
4.006.007.8M15.6MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26RLMDclose 4.4720-day 3.6150-day 3.78200-day 5.364.4752w low

44.2% under the 52-week high of 8.00 on 6 May 2026. 52-week low 2.97 on 11 Nov 2025. Last 15 sessions, 46.0% high to low

Profile

RLMD
52-week range, 30% of the way up
2.978.00

Relmada Therapeutics, Inc. engages in the development of clinical-stage drugs. The firm's pipeline includes NDV-01 and Sepranolone. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.

IndexRUT
Employees17
IPOJun 20, 2014
Beta0.55
ATR, 14d0.28
Rel volume0.77
Short float11.68%
Insider own13.01%
Inst own84.49%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap476.28M
Enterprise Value258.55M
Income-61.93M
Sales0.00M
Book/sh1.94
Cash/sh2.04
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees17
IPOJun 20, 2014

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B2.31
P/C2.19
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio29.52
Current Ratio29.52
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.93
EPS next Y-0.80
EPS next Q-0.14
EPS this Y57.07%
EPS next Y-28.11%
EPS next 5Y20.09%
EPS past 3/5Y35.03% 17.54%
Sales past 3/5Y- -
EPS Y/Y TTM57.98%
Sales Y/Y TTM-
EPS Q/Q61.35%
Sales Q/Q-
EarningsNov 12 AMC
EPS/Sales Surpr.44.86% -

Ownership

Insider Own13.01%
Insider Trans2.97%
Inst Own84.49%
Inst Trans16.66%
ROA-51.57%
ROE-55.66%
ROIC-29.98%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA2023.64%
SMA5018.14%
SMA200-16.77%
Trades-

Technical

Shs Outstand106.67M
Shs Float92.79M
Short Float11.68%
Short Ratio7.94
Short Interest10.84M
52W High8.00 -44.19%
52W Low2.97 50.33%
Volatility9.76% 7.34%
ATR (14)0.28
RSI (14)66.71
Beta0.55
Rel Volume0.77
Avg Volume1.36M
Volume816,876

Performance

Perf Week7.07%
Perf Month32.89%
Perf Quarter-6.00%
Perf Half Y-40.39%
Perf YTD-7.56%
Perf Year35.71%
Perf 3Y53.97%
Perf 5Y-82.60%
Perf 10Y24.03%
Recom1.00
Target Price10.75
Prev Close4.27
Price4.47
Change %4.57%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Jun 18, 2026InitiatedHH.C. WainwrightBuy$12+168.8%
Mar 24, 2026InitiatedPPiper SandlerOverweight$12+168.8%
Jan 23, 2026ResumedLLeerink PartnersOutperform$8+79.2%
Dec 22, 2025InitiatedJJefferiesBuy$69+1,445.4%
Nov 19, 2025UpgradeMMizuhoNeutral → Outperform$10+124.0%
Dec 05, 2024DowngradeMMizuhoOutperform → Neutral$23 → $1-77.6%
Sep 17, 2024UpgradeJJefferiesHold → Buy$3.50 → $13+191.2%
Jun 05, 2024DowngradeGGoldmanNeutral → Sell$3 → $2-55.2%
Oct 14, 2022DowngradeTTruistBuy → Hold$90 → $10+124.0%
Oct 14, 2022DowngradeGGuggenheimBuy → Neutral

Peers

Mkt cap
TickerCompanyMkt cap
URGNUroGen Pharma Ltd1.27B
CGONCg Oncology Inc6.55B
ENGNenGene Therapeutics Inc118.96M
TARAProtara Therapeutics Inc165.32M
ARTVArtiva Biotherapeutics Inc203.91M
SPTXSeaport Therapeutics Inc1.12B
ZVRAZevra Therapeutics Inc709.58M
XENEXenon Pharmaceuticals Inc4.10B
RZLTRezolute Inc396.10M
ACADAcadia Pharmaceuticals Inc3.18B

Insider trading

6 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Shenouda MagedChief Financial OfficerSep 09 '26Buy4.20120,200504,840920,200Sep 11 07:30 AM
Shenouda MagedChief Financial OfficerSep 10 '26Buy4.2579,800339,1501,000,000Sep 11 07:30 AM
TRAVERSA SERGIOChief Executive OfficerSep 09 '26Buy4.18100,000418,0001,400,000Sep 11 07:30 AM
TRAVERSA SERGIOChief Executive OfficerSep 10 '26Buy4.10100,000410,0001,500,000Sep 11 07:30 AM
TRAVERSA SERGIOChief Executive OfficerDec 15 '25Buy4.1227,500113,3001,300,000Dec 16 09:30 AM
Shenouda MagedChief Financial OfficerDec 15 '25Buy4.1211,66548,060800,000Dec 16 09:30 AM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
XPHState Street SPDR S&P Pharmaceuticals ETFAUM: 516.35M
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
PSILAdvisorShares Psychedelics ETFAUM: 43.26M
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWCiShares Micro-Cap ETFAUM: 1.22B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
VHTVanguard Health Care ETFAUM: 21.51B

News

latest 14 of 200
  • Relmada's Q3 Report Is A Test Of Whether NDV-01's Year-End IND Timeline Holds (Earnings Whispers) -9.59%
  • Relmada Therapeutics to Participate at the Jefferies Global Healthcare Conference in London (GlobeNewswire)
  • Relmada Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, November 12, 2026 (GlobeNewswire) +11.20%
  • Relmada Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference (GlobeNewswire)
  • Relmada Therapeutics Inc (RLMD) (Q2 2026) Earnings Call Highlights: Strong Phase 2 Data and FDA ... (GuruFocus.com) -8.01%
  • Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
  • Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer (GlobeNewswire)
  • Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026 (GlobeNewswire) -12.08%
  • Relmada Therapeutics Joins Russell 2000 and Russell 3000 Indexes (GlobeNewswire)
  • Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program (GlobeNewswire)
  • Relmada Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
  • Relmada Therapeutics Inc (RLMD) Q1 2026 Earnings Call Highlights: Strong Financial Position and ... (GuruFocus.com)
  • Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
  • Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026 (GlobeNewswire) +6.94%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-12--0.145--0.004
2026Q22026-08-06-0.110-0.200-0.1100.000.006
2026Q12026-05-12-0.220-0.200-0.2200.000.005
2025Q42026-03-19-0.270-0.149-0.2910.000.004
2025Q32025-11-13-0.300-0.424-0.3040.000.001
2025Q22025-08-07-0.300-0.460-0.2970.000.001
2025Q12025-05-12-0.580-0.480-0.5770.000.001
2024Q42025-03-27-0.620-0.673-0.6180.000.003
2024Q32024-11-07-0.720-0.675-0.7200.000.004
2024Q22024-08-07-0.590-0.828-0.5890.000.004
2024Q12024-05-08-0.720-0.850-0.7240.000.005
2023Q42024-03-19-0.840-0.830-0.8360.000.005
2023Q32023-11-08-0.730-0.914-0.7310.000.005
2023Q22023-08-08-0.840-0.895-0.8410.000.006
2023Q12023-05-11-0.870-0.890-0.8750.000.004
2022Q42023-03-23-1.280-1.328-1.2610.000.006

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2016FY-1.040-0.520-1.0400.000.00
2020FY-3.810-3.540-3.8130.000.00
2021FY-7.160-6.839-7.1640.000.00
2022FY-5.300-5.370-5.3000.000.00
2023FY-3.280-3.276-3.2820.000.00
2024FY-2.650-2.703-2.6520.000.00
2025FY-1.450-1.048-1.4500.000.00
2026FY--0.623--0.00
2027FY--0.798--0.00
2028FY--0.740--0.00
2029FY--0.825--4.90
2030FY--0.425--79.78

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-08-273000.000.000.00
2026Q3S2026-08-214000.000.000.00
2026Q3S2026-08-075000.000.000.00
2026Q3S2026-08-065000.000.000.00
2026Q3S2026-06-175000.000.000.00
2026Q3S2026-05-134000.000.000.00
2026Q3S2026-03-234000.000.000.00
2026Q3S2026-03-203000.000.000.00
2026Q3S2026-02-271000.000.000.00
2026Q3R2026-10-21100-0.14-0.14-0.14
2026Q3R2026-09-14110-0.14-0.14-0.14
2026Q3R2026-08-07220-0.13-0.14-0.12
2026Q3R2026-08-06200-0.17-0.20-0.13
2026Q3R2026-07-27200-0.17-0.20-0.13

Estimate history

EPS, annual-1.04-2.08-2.84-3.813-7.164-5.3-3.282-2.652-1.454-0.93
Period201620172018202020212022202320242025TTM
EPS, quarterly-0.589-0.72-0.618-0.577-0.297-0.304-0.291-0.22-0.115
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0000000000
Period201620172018202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual3.0093.1323.13716.33327.7430.09930.09930.17473.334106.67
Period201620172018202020212022202320242025MRQ
Shares, quarterly30.17430.17430.17433.19233.19233.19273.334104.89106.67
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2018FY
Total Revenue0.000.000.000.000.000.000.00-0.00
Cost of Goods Sold Incl. D&A0.000.000.000.000.000.000.00-0.00
Gross Profit0.000.000.000.000.00-0.00-0.00--0.00
Selling, General and Administrative Excl. Other65.1359.1083.89103.70161.25125.7060.83-6.91
Research and Development28.5926.8846.1854.81113.3290.6235.97-2.94
Other Operating Expense0.000.000.000.000.000.000.00-0.00
Operating Income-65.13-59.10-83.89-103.70-161.25-125.70-60.84--6.92
Interest Expense0.000.000.000.000.000.000.00-1.34
Unusual Expense0.45-0.40-0.01-3.82-2.130.61-0.14-0.71
Net Income Before Taxes-61.93-57.39-79.98-98.79-157.04-125.75-59.46--8.96
Income Taxes0.000.000.000.000.000.000.00-0.00
Consolidated Net Income-61.93-57.39-79.98-98.79-157.04-125.75-59.46--8.96
Net Income From Continuing Operations-61.93-57.39-79.98-98.79-157.04-125.75-59.46--8.96
Net Income-61.93-57.39-79.98-98.79-157.04-125.75-59.46--8.96
EPS (Recurring)-0.55-1.46-2.65-3.37-5.35-7.14-3.82--2.70
EPS (Basic, Before Extraordinaries)-0.93-1.45-2.65-3.28-5.30-7.16-3.81--2.84
EPS (Diluted)-0.93-1.45-2.65-3.28-5.30-7.16-3.81--2.84
EBITDA-65.13-59.10-83.89-103.70-161.25-125.70-60.83--6.91
Non-Operating Income (Expense)3.661.323.901.092.070.561.24-0.00
Other After Tax Adjustments0.000.000.000.000.000.000.00-0.00
Stock Option Compensation Expense8.7414.8130.1843.8144.1940.4920.78-0.52
Shares Outstanding106.6773.3330.1730.1030.1027.7416.33-3.14
Market Capitalization455.48455.4815.69124.61105.05394.97520.86-12.67

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.000.000.000.000.000.00
Gross Profit0.000.000.000.000.000.000.000.00
Selling, General and Administrative Excl. Other15.0119.4620.3310.3310.2218.2219.0823.01
Research and Development8.398.098.074.042.8211.9511.0011.15
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-15.01-19.46-20.33-10.33-10.22-18.22-19.08-23.01
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.170.54-0.19-0.070.01-0.160.28-0.28
Net Income Before Taxes-12.91-19.05-19.87-10.09-9.87-17.56-18.66-21.73
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-12.91-19.05-19.87-10.09-9.87-17.56-18.66-21.73
Net Income From Continuing Operations-12.91-19.05-19.87-10.09-9.87-17.56-18.66-21.73
Net Income-12.91-19.05-19.87-10.09-9.87-17.56-18.66-21.73
EPS (Recurring)-0.11-0.22-0.29-0.31-0.30-0.58-0.61-0.73
EPS (Basic, Before Extraordinaries)-0.11-0.22-0.29-0.30-0.30-0.58-0.62-0.72
EPS (Diluted)-0.11-0.22-0.29-0.30-0.30-0.58-0.62-0.72
EBITDA-15.01-19.46-20.33-10.33-10.22-18.22-19.08-23.01
Non-Operating Income (Expense)2.260.950.280.170.370.500.701.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.900.963.283.613.454.486.737.95
Shares Outstanding106.67104.8973.3333.1933.1933.1930.1730.17
Market Capitalization455.48730.03354.2066.7219.928.1515.6997.76

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2018FY2017FY
Cash & Short Term Investments93.0144.9196.32148.32211.91117.09-2.241.71
Short Term Receivables0.000.000.000.510.090.08-0.070.29
Inventories0.000.000.000.000.000.00-0.000.00
Other Current Assets0.980.891.194.0411.300.90-0.430.47
Total Current Assets93.9845.8097.51152.87223.30118.07-2.742.47
Net Property, Plant & Equipment0.000.000.000.000.000.00-0.010.00
Total Investments and Advances0.000.000.000.000.000.00-0.000.00
Long-Term Note Receivable----0.000.09-0.270.34
Other Assets0.020.020.040.030.030.03-0.020.02
Total Assets94.0045.8297.55152.91223.33118.19-3.052.84
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.000.00-0.290.28
Accounts Payable1.574.133.515.2611.198.35-0.770.53
Other Current Liabilities4.866.168.697.213.874.26-4.850.57
Total Current Liabilities6.4310.2912.1912.4715.0612.60-5.901.38
Long Term Debt0.000.000.000.000.000.00-2.660.00
Provision for Risks Charges0.000.000.000.000.000.00-0.000.00
Other Liabilities1.060.000.000.000.000.00-0.000.00
Total Liabilities7.4910.3012.1912.4715.0612.60-8.561.38
Non-Equity Reserves0.000.000.000.000.000.00-0.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00-0.000.00
Common Equity86.5135.5285.36140.44208.26105.58--5.511.46
Total Shareholders Equity86.5135.5285.36140.44208.26105.58--5.511.46
Accumulated Minority Interest0.000.000.000.000.000.00-0.000.00
Total Equity86.5135.5285.36140.44208.26105.58--5.511.46
Total Liabilities & Stockholders Equity94.0045.8297.55152.91223.33118.19-3.052.84
Book Value Per Share1.181.182.844.677.516.46--1.760.47
Tangible Book Value Per Share1.181.182.844.677.516.46--1.760.47
Full-Time Employees171720141014-33
Price to Book Ratio2.210.331.240.603.004.96--5.477.04
Return on Assets-82.08-111.57-78.89-83.48-73.64-92.61--304.53-96.12
Return on Equity-94.05-132.33-87.51-90.07-80.14-105.05---147.87
Return on Invested Capital-66.33-225.15-115.74-111.83-60.38-56.31---430.50
Quick Ratio14.624.458.0012.2614.839.37-0.461.80
Current Ratio14.624.458.0012.2614.839.37-0.461.80

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2018FY
Net Income-61.93-57.39-79.98-98.79-157.04-125.75-59.46--8.96
Depreciation----0.000.000.00-0.00
Other Funds (Non Cash)14.5115.5529.8144.0542.6541.7420.79-2.26
Funds from Operations-47.42-41.84-50.17-54.74-114.39-84.01-38.66--6.70
Extraordinary Item0.000.000.000.000.000.000.00-0.00
Changes in Working Capital1.43-3.95-1.583.0810.59-7.8610.85-0.70
Cash from Operating Activities-45.99-45.79-51.76-51.66-103.80-91.87-27.81--6.00
Capital Expenditures0.000.000.000.000.000.000.00--0.01
Net Assets From Acquisitions0.000.000.000.000.000.000.00--
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.00--
Purchase or Sale of Investments-187.82-48.1451.5650.4519.73-54.12-34.45-0.00
Purchase of Investments-257.29-83.83-12.08-90.46-47.29-222.98-182.05--
Sale Or Maturity of Investments69.4735.6963.64140.9267.03168.86147.60-0.00
Other Uses0.000.000.000.000.000.000.00-0.00
Other Sources0.000.000.000.000.000.000.00-0.00
Cash from Investing Activities-187.82-48.1451.5650.4519.73-54.12-34.45--0.01
Cash Dividends Paid0.000.000.000.000.000.000.00-0.00
Change in Capital Stock243.9293.640.250.0044.65187.9428.58-0.00
Repurchase of Common Pref Stock0.000.000.000.000.000.000.00-0.00
Sale of Common Pref Stock243.9293.640.250.0044.65187.9428.58-0.00
Proceedsfrom Stock Options83.9293.640.000.0042.63184.6419.79-0.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00-0.11-6.54
Change in Long Term Debt0.000.000.000.000.000.000.00-6.53
Issuance of Long Term Debt0.000.000.000.000.000.000.00-6.53
Reduction of Long Term Debt0.000.000.000.000.000.000.00-0.00
Net Financing Active Other Cash Flow-0.13-0.07-0.29-0.100.370.000.00-0.00
Other Financing Activities Uses-0.13-0.07-0.29-0.100.000.000.00-0.00
Cash from Financing Activities243.7993.56-0.04-0.1045.02187.9428.47-6.54
Net Change in Cash9.98-0.36-0.23-1.30-39.0541.95-33.78-0.53
Free Cash Flow-45.99-45.79-51.76-51.66-103.80-91.87-27.81--6.01
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.00-0.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.00-0.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments217.73233.9693.0113.8920.6227.06
Short Term Receivables0.010.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets1.301.380.980.970.470.60
Total Current Assets219.04235.3493.9814.8521.0927.66
Net Property, Plant & Equipment0.000.000.000.000.000.00
Total Investments and Advances0.000.000.000.000.000.00
Other Assets0.020.020.020.020.020.02
Total Assets219.06235.3694.0014.8821.1227.68
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.000.00
Accounts Payable2.415.731.571.451.361.27
Other Current Liabilities5.017.164.863.743.773.97
Total Current Liabilities7.4212.896.435.195.135.23
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities5.083.741.060.220.030.01
Total Liabilities12.5016.637.495.415.175.24
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity206.56218.7386.519.4715.9522.44
Total Shareholders Equity206.56218.7386.519.4715.9522.44
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity206.56218.7386.519.4715.9522.44
Total Liabilities & Stockholders Equity219.06235.3694.0014.8821.1227.68
Book Value Per Share1.942.091.180.290.480.68
Tangible Book Value Per Share1.942.091.180.290.480.68
Full-Time Employees--17---
Price to Book Ratio2.215.9016.944.180.890.23
Return on Assets-51.57-44.77-82.08-159.13-147.18-135.09
Return on Equity-55.66-48.83-94.05-196.79-175.12-160.26
Return on Invested Capital-6.25-8.71-22.97-106.61-61.86-78.25
Quick Ratio29.5218.2614.622.864.115.29
Current Ratio29.5218.2614.622.864.115.29

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-12.91-19.05-19.87-10.09-9.87-17.56
Other Funds (Non Cash)2.454.184.043.843.424.26
Funds from Operations-10.47-14.87-15.83-6.26-6.45-13.30
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.86-0.201.23-0.470.05-4.77
Cash from Operating Activities-9.61-15.07-14.60-6.72-6.40-18.07
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments17.59-135.23-76.936.756.6815.36
Purchase of Investments-24.75-149.52-82.79-0.23-0.32-0.49
Sale Or Maturity of Investments42.3414.295.866.997.0015.85
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities17.59-135.23-76.936.756.6815.36
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-6.35156.6493.640.000.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock-6.35156.6493.640.000.000.00
Proceedsfrom Stock Options-6.35-3.3693.640.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.07-0.070.000.00-0.070.00
Other Financing Activities Uses-0.07-0.070.000.00-0.070.00
Cash from Financing Activities-6.42156.5793.640.00-0.070.00
Net Change in Cash1.566.282.110.030.20-2.71
Free Cash Flow-9.61-15.07-14.60-6.72-6.40-18.07

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3011.68%10.8M92.8M1.33M
2026-10-1513.13%12.2M92.8M1.34M
2026-09-3014.47%13.4M92.8M1.36M
2026-09-1515.59%14.5M92.8M1.75M
2026-08-3114.63%13.6M93.0M1.71M
2026-08-1413.87%12.9M92.9M1.77M
2026-07-3114.75%13.6M92.0M1.68M
2026-07-1514.37%13.0M90.4M1.61M
2026-06-3011.78%10.6M90.4M1.58M
2026-06-156.70%6.1M90.4M1.23M
2026-05-296.34%5.8M92.1M1.87M
2026-05-155.96%5.5M92.1M1.84M
2026-04-305.81%5.3M92.0M1.80M
2026-04-156.73%6.2M92.0M1.67M
2026-03-316.98%6.0M86.5M1.54M
2026-03-134.31%3.7M86.5M1.44M
2026-02-271.38%0.8M60.5M733.60K
2026-02-131.84%1.1M60.5M804.94K
2026-01-301.99%1.3M63.1M1.23M
2026-01-152.27%1.4M63.1M1.15M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.501.552.300.655.0389040.000.946-0.0120.001
call5.000.050.200.181.4081,2103110.343-0.0200.003
call7.500.000.350.043.7655740.000.281-0.0500.002
call10.000.000.150.343.76139.000.000.141-0.0330.002
call12.500.000.151.004.42425.000.000.127-0.0360.001
call15.000.000.100.054.5352.000.000.088-0.0280.001
put2.500.000.050.054.0731.000.00-0.108-0.0300.001
put5.000.301.051.002.57354.000.00-0.657-0.0200.003
put7.502.753.602.104.6611.000.00-0.796-0.0340.002
put10.005.206.200.006.1270.000.00-0.858-0.0320.002
put12.507.708.800.007.3260.000.00-0.873-0.0350.001
put15.0010.2011.300.007.8870.000.00-0.912-0.0270.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-09-114Statement of changes in beneficial ownership of securities2026-09-09SEC
2026-09-114Statement of changes in beneficial ownership of securities2026-09-09SEC
2026-09-088-KCurrent report2026-09-03SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-068-KCurrent report2026-08-06SEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-29SCHEDULE 13GSEC
2026-07-288-KCurrent report2026-07-28SEC
2026-06-22SCHEDULE 13GSEC
2026-06-18S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-06-09SCHEDULE 13GSEC
2026-05-288-KCurrent report2026-05-27SEC
2026-05-13S-3ASRAutomatic shelf registration statement of securities of well-known seasoned issuersSEC
2026-05-13SCHEDULE 13G/ASEC
2026-05-128-KCurrent report2026-05-12SEC
2026-05-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-04SCHEDULE 13GSEC
2026-04-17DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-17DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-05-27SEC
2026-04-09EFFECTEffectiveness filing by commission orderSEC
2026-04-09424B3SEC
2026-04-07CORRESPSEC
2026-04-07UPLOADUpload SubmissionSEC
2026-04-06PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-04-06SEC
2026-04-03S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-03-208-KCurrent report2026-03-19SEC
2026-03-1910-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-098-KCurrent report2026-03-09SEC
2026-02-17SCHEDULE 13G/ASEC
2026-02-17SCHEDULE 13GSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-091.67M400
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-12161.36K200
2025-112.20M400

Institutional holders

Manager% owned
Jupiter Topco LLC10.64%
BlackRock, Inc.7.08%
Squadron Capital Management LLC7.01%
Venrock Adviser, LLC6.53%
Spruce Street Capital LP6.09%
ADAGE CAPITAL PARTNERS GP, L.L.C.4.54%
VANGUARD CAPITAL MANAGEMENT LLC4.25%
Jones Hill Capital LP3.48%
ORBIMED ADVISORS LLC3.46%
STATE STREET CORP2.40%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND3.02%
iShares Russell 2000 ETF1.99%
VANGUARD EXTENDED MARKET INDEX FUND1.15%
Fidelity Small Cap Index Fund0.99%
iShares Russell 2000 Growth ETF0.83%
Eventide Healthcare & Life Sciences Fund0.80%
Franklin Biotechnology Discovery Fund0.75%
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF0.62%
VANGUARD RUSSELL 2000 INDEX FUND0.51%
Fidelity Extended Market Index Fund0.43%

OakChart. RLMD. Cached 15 minutes.